(GMAB) Genmab AS - Ratings and Ratios

Genmab A/S is a leading biotechnology company specializing in the development of antibody-based therapies for cancer and other diseases. Headquartered in Copenhagen, Denmark, the company has established a robust pipeline of approved and investigational products targeting hematologic malignancies and solid tumors. Its commercialized products include EPKINLY and TEPKINLY for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), as well as Tivdak for recurrent/metastatic cervical cancer. The company is also advancing a diverse clinical-stage pipeline, including Epcoritamab for multiple B-cell malignancies, tisotumab vedotin for solid tumors, and several bispecific antibodies such as GEN1042 and GEN1059 for solid tumors.

Genmab has a strong track record of collaborations with major pharmaceutical companies, including AbbVie, Pfizer, BioNTech, and Novartis, leveraging its antibody expertise to co-develop innovative therapies. The companys product portfolio also includes DARZALEX/DARZALEX FASPRO for multiple myeloma, RYBREVANT for NSCLC, and Kesimpta for relapsing multiple sclerosis. Its pipeline extends to early-stage research in areas such as head and neck cancer, colorectal cancer, and rare diseases like multiple system atrophy and hemophilia A.

Genmab A/S was founded in 1998 and has grown into a global biotech player with a market capitalization of $12.54 billion USD. The company trades on the NASDAQ under the ticker GMAB, with a trailing P/E of 10.89 and a forward P/E of 11.11, indicating moderate valuation relative to earnings. Its price-to-book ratio of 2.26 reflects the markets confidence in its intangible assets and pipeline potential. The companys return on equity (RoE) of 21.38% underscores its operational efficiency and profitability.